Holen Sie sich die Stockscreener-App
78.07
1.16%
-0.92
Schlusskurs vom Vortag:
$78.99
Offen:
$79.11
24-Stunden-Volumen:
1.30M
Relative Volume:
1.94
Marktkapitalisierung:
$4.03B
Einnahmen:
$379.25M
Nettoeinkommen (Verlust:
$-77.34M
KGV:
-48.42
EPS:
-1.6122
Netto-Cashflow:
$-27.87M
1W Leistung:
-1.50%
1M Leistung:
+11.72%
6M Leistung:
+59.03%
1J Leistung:
+85.70%
1-Tages-Spanne:
$75.98
$80.00
1-Wochen-Bereich:
$75.98
$80.46
52-Wochen-Spanne:
$36.88
$82.58
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Firmenname
Mirum Pharmaceuticals Inc
Sektor
Branche
Telefon
650-667-4085
Adresse
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Vergleichen Sie MIRM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
78.07 | 4.08B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-24 | Eingeleitet | TD Cowen | Buy |
| 2025-08-11 | Fortgesetzt | Stifel | Buy |
| 2025-05-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-04-17 | Eingeleitet | Stifel | Buy |
| 2023-12-18 | Bestätigt | H.C. Wainwright | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-11-13 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-09-20 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2021-09-20 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-07 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-25 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-12 | Eingeleitet | Citigroup | Buy |
| 2019-08-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-12 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-12 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Mirum Pharmaceuticals Inc Aktie (MIRM) Neueste Nachrichten
Mirum Pharmaceuticals (NASDAQ:MIRM) Downgraded by Wall Street Zen to "Buy" - MarketBeat
Aug Reactions: Will Mirum Pharmaceuticals Inc. stock pay special dividendsStop Loss & Reliable Volume Spike Alerts - moha.gov.vn
Price-Driven Insight from (MIRM) for Rule-Based Strategy - Stock Traders Daily
Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now - Finviz
Mirum Pharmaceuticals to raise $68.5M in private placement with TCGX - MSN
Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line - Yahoo Finance
Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line - The Motley Fool
Rice Hall James & Associates LLC Sells 67,247 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals Earnings Notes - Trefis
Mirum Pharmaceuticals price target raised to $88 from $80 at Baird - MSN
What Analysts Think Is Changing the Story for Mirum Pharmaceuticals Now - Yahoo Finance
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Mirum Pharma director Grey sells $3.9 million in stock By Investing.com - Investing.com Nigeria
Mirum pharmaceuticals director Saira Ramasastry sells $400k in shares By Investing.com - Investing.com Canada
Mirum pharmaceuticals director Saira Ramasastry sells $400k in shares - Investing.com
Mirum Pharmaceuticals Executives Sell Shares - TradingView — Track All Markets
Mirum Pharma director Grey sells $3.9 million in stock - Investing.com
This Biotech Name Outperforms 93% Of Stocks, And It's In A Buy Zone - Investor's Business Daily
Mirum Pharmaceuticals joins elite list of stocks with 95-plus composite rating - MSN
Guidance Update: Will Mirum Pharmaceuticals Inc 08D stock sustain uptrend momentumPortfolio Return Summary & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
Mirum Pharmaceuticals: Rich In 2025, Richer (In Promise) In 2026? I Believe So (MIRM) - Seeking Alpha
Mirum: Maintaining Buy Rating On VOLIXIBAT PSC Treatment Data Q2 2026 (NASDAQ:MIRM) - Seeking Alpha
Squarepoint Ops LLC Decreases Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
How (MIRM) Movements Inform Risk Allocation Models - Stock Traders Daily
Can Mirum Pharmaceuticals Inc. stock maintain growth trajectoryTrade Risk Summary & Real-Time Market Trend Scan - Улправда
Signal Recap: Will Mirum Pharmaceuticals Inc. (08D) stock hit Wall Street targets2025 Market WrapUp & Verified Momentum Watchlists - Улправда
Will Mirum Pharmaceuticals Inc. stock pay special dividends2025 Macro Impact & Risk Adjusted Buy and Sell Alerts - Улправда
How Mirum Pharmaceuticals Inc. stock compares to growth peersMarket Growth Summary & Low Drawdown Momentum Trade Ideas - Улправда
Mirum Pharmaceuticals Surges Following Strategic Moves and Analyst Ratings - timothysykes.com
Mirum Pharmaceuticals Raises Capital via Private Placement - The Globe and Mail
Is Mirum Pharmaceuticals Inc. stock supported by strong fundamentalsM&A Rumor & High Accuracy Trade Signal Alerts - Улправда
Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 52-Week High Following Analyst Upgrade - MarketBeat
Mirum Pharmaceuticals files patent suits to block generic Livmarli approval By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals: Bluejay Acquisition Boost - StocksToTrade
Citizens Maintains Mirum Pharmaceuticals (MIRM) Market Outperform Recommendation - Nasdaq
Mirum Pharmaceuticals files patent suits to block generic Livmarli approval - Investing.com
Mirum Files Patent Suits to Block Livmarli Generics - TipRanks
Mirum Pharmaceuticals stock hits all-time high at 78.55 USD By Investing.com - Investing.com Nigeria
Mirum secures $68.5 million in private placement ahead of acquisition By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals stock hits all-time high at 78.55 USD - Investing.com
Mirum Pharmaceuticals (MIRM) Stock Jumps on New $68.5M TCGX Financing, Bluejay Deal Momentum, and a Fresh $140 Price Target - ts2.tech
Mirum Pharmaceuticals (NASDAQ:MIRM) Trading Up 8.9% Following Analyst Upgrade - MarketBeat
Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX - Investing News Network
Mirum Pharmaceuticals announces additional private placement financing with TCGX - marketscreener.com
Mirum Pharmaceuticals Agrees to $68.5 Million Equity Private Placement - marketscreener.com
Mirum secures $68.5 million in private placement ahead of acquisition - Investing.com
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $140.00 - MarketBeat
Finanzdaten der Mirum Pharmaceuticals Inc-Aktie (MIRM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):